Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunological Effects of Convalescent Plasma Therapy for Coronavirus: A Scoping Review Publisher Pubmed



Esmaeili B1 ; Esmaeili S2 ; Pourpak Z1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Immunology, Asthma and Allergy Research Institute (IAARI), Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: BMC Infectious Diseases Published:2021


Abstract

Background: Preliminary studies revealed the safety and effectiveness of convalescent plasma (CP) therapy for patients with coronavirus. In this study, we aimed to evaluate and summarize the available evidence on CP therapy, identify the research gap regarding the immunological response to CP therapy and pave the road for future studies. Methods: This study was conducted according to the Hilary Arksey and Lisa O’Malley framework. To find out the relevant studies, we searched PubMed, Scopus and Embase databases up to 30th May 2021. Data have been extracted according to three categories: (1) patients’ characteristics, (2) clinical and immunological responses to CP therapy and (3) pre-infusion screening of the CP samples. Results: A total of 12,553 articles were identified. One hundred fifty-four studies met the inclusion criteria for full-text review. More than half of the included studies (112 studies, (75.6%)) concluded satisfactory outcomes and or safety of CP infusion in patients. Results of studies showed the efficacy of CP therapy in clinical improvement (101 studies), decreasing in the level of inflammatory factors (62 studies), elimination or decreasing in viral load (60 studies), and induction or increase in antibody response (37 studies). Despite these promising results, the results of the 49 studies revealed that CP therapy was ineffective in the survival of patients, clinical improvement, viral infection elimination or decrease in the inflammatory factor levels. Furthermore, the adaptive immune response was evaluated in 3 studies. Information related to the pre-infusion screening for human leukocyte antigen/human neutrophil antigen (HLA/HNA) antibodies was not reported in most of the studies. Our gap analysis revealed that the influence of the CP infusion on the adaptive immune and inflammatory responses in patients with coronavirus needs further investigation. Conclusions: Based on the results of most included studies, CP infusion was safe and resulted in clinical improvement of patients and decreasing the viral load. The effect of the CP infusion on adaptive immune response and inflammatory cytokines in patients with coronavirus needs further investigation. © 2021, The Author(s).
Other Related Docs
14. Potential Therapeutic Options for Covid-19: An Update on Current Evidence, European Journal of Medical Research (2022)
16. Dynamic Changes of Lymphocyte Subsets in the Course of Covid-19, International Archives of Allergy and Immunology (2021)
17. Novel Therapeutic Approaches for Treatment of Covid-19, Journal of Molecular Medicine (2020)
18. Immune-Based Therapy for Covid-19, Advances in Experimental Medicine and Biology (2021)
20. Advances in Immunotherapy for Covid-19: A Comprehensive Review, International Immunopharmacology (2021)
25. Potential Therapeutic Approach of Intravenous Immunoglobulin Against Covid-19, Allergy# Asthma and Clinical Immunology (2021)
31. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)